Along with those clinical trials explained earlier mentioned, there have also been pre-clinical studies that showed excellent general performance with regard to the two safety and effectiveness against AML. For all flow cytometry experiments, 10,000 cells per replicate have been analyzed, and 3 replicates for each ailment were analyzed per https://abbv-744-brd4-inhibitor-m12467.pointblog.net/about-abbv-744-in-clinical-trials-for-non-small-cell-lung-cancer-nsclc-74764271